AU3024399A
(en)
|
1998-04-03 |
1999-10-25 |
Bm Research A/S |
Controlled release composition
|
CA2328628A1
(en)
*
|
1999-12-21 |
2001-06-21 |
Cecile J. Schoenheider |
Moldable compositions
|
US20070059367A1
(en)
*
|
2000-06-06 |
2007-03-15 |
Cherukuri S R |
Drug Delivery System and Associated Methods
|
US20100196466A1
(en)
*
|
2000-06-06 |
2010-08-05 |
Capricorn Pharma Inc. |
Drug delivery system
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
US20040122090A1
(en)
*
|
2001-12-07 |
2004-06-24 |
Lipton Stuart A. |
Methods for treating neuropsychiatric disorders with nmda receptor antagonists
|
WO2002055009A1
(en)
*
|
2001-01-12 |
2002-07-18 |
Sun Pharmaceutical Industries Limited |
Spaced drug delivery system
|
EP1377276B1
(en)
*
|
2001-04-10 |
2011-10-05 |
Sun Pharma Advanced Research Company Limited |
Timed pulse release composition
|
IN191028B
(pt)
*
|
2001-05-17 |
2003-09-13 |
Sun Pharmaceutical Ind Ltd |
|
US6838093B2
(en)
*
|
2001-06-01 |
2005-01-04 |
Shire Laboratories, Inc. |
System for osmotic delivery of pharmaceutically active agents
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US20030050620A1
(en)
*
|
2001-09-07 |
2003-03-13 |
Isa Odidi |
Combinatorial type controlled release drug delivery device
|
US20030091634A1
(en)
*
|
2001-09-14 |
2003-05-15 |
Pawan Seth |
Delayed release tablet of venlafaxin
|
WO2003024429A1
(en)
|
2001-09-21 |
2003-03-27 |
Egalet A/S |
Polymer release system
|
EP1429744A1
(en)
|
2001-09-21 |
2004-06-23 |
Egalet A/S |
Morphine polymer release system
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
MY148466A
(en)
*
|
2001-10-26 |
2013-04-30 |
Merck Frosst Canada Ltd |
Granule formulation
|
US8329217B2
(en)
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
CA2471096A1
(en)
*
|
2001-12-19 |
2003-07-03 |
Alza Corporation |
Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
|
US20040052843A1
(en)
*
|
2001-12-24 |
2004-03-18 |
Lerner E. Itzhak |
Controlled release dosage forms
|
EP1490029A4
(en)
*
|
2002-03-22 |
2006-02-22 |
Ranbaxy Lab Ltd |
DRUG DELIVERY SYSTEM WITH CONTROLLED RELEASE OF PRAVASTATIN
|
US20050175697A1
(en)
*
|
2003-12-29 |
2005-08-11 |
David Edgren |
Novel drug compositions and dosage forms of topiramate
|
US7771707B2
(en)
|
2004-06-12 |
2010-08-10 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent drug formulations
|
AU2003256844A1
(en)
*
|
2002-07-29 |
2004-02-16 |
Alza Corporation |
Methods and dosage forms for controlled delivery of paliperidone
|
US20050232995A1
(en)
*
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
CA2494233A1
(en)
*
|
2002-07-29 |
2004-02-05 |
Alza Corporation |
Formulations and dosage forms for controlled delivery of topiramate
|
US20090162431A1
(en)
*
|
2002-09-21 |
2009-06-25 |
Shuyi Zhang |
Sustained release formulations containing acetaminophen and tramadol
|
DE60319252T2
(de)
*
|
2002-09-21 |
2009-03-05 |
Zhang, Shuyi |
Formulierung von acetaminophen und tramadol mit verzögerter freisetzung
|
WO2004041252A1
(en)
|
2002-11-08 |
2004-05-21 |
Egalet A/S |
Controlled release carvedilol compositions
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
US8293799B2
(en)
*
|
2003-12-29 |
2012-10-23 |
Osmotica Keresleedelmo és Szolgáltató KFT |
Osmotic device containing a venlafaxine salt and a salt having an ion in common
|
EP1610767B1
(en)
|
2003-03-26 |
2011-01-19 |
Egalet A/S |
Morphine controlled release system
|
EP1974726B1
(en)
|
2003-03-26 |
2010-01-13 |
Egalet A/S |
Matrix compositions for controlled delivery of drug substances
|
US20060210633A1
(en)
*
|
2003-04-03 |
2006-09-21 |
Sun Pharmaceutical Industries Limited |
Programmed drug delivery system
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
US7226968B2
(en)
*
|
2003-05-20 |
2007-06-05 |
Arch Uk Biocides Limited |
Composition and use
|
US7217759B2
(en)
*
|
2003-05-20 |
2007-05-15 |
Arch Uk Biocides Limited |
Composition and use
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
US20050176693A1
(en)
*
|
2003-08-12 |
2005-08-11 |
Boissonneault Roger M. |
Method of intermittent administration of a pharmaceutical for the treatment of conditions associated with a female's menstrual cycle
|
US7611728B2
(en)
*
|
2003-09-05 |
2009-11-03 |
Supernus Pharmaceuticals, Inc. |
Osmotic delivery of therapeutic compounds by solubility enhancement
|
AU2004314693B2
(en)
|
2003-09-26 |
2011-04-07 |
Alza Corporation |
Drug coating providing high drug loading and methods for providing the same
|
AU2004275835B2
(en)
*
|
2003-09-26 |
2011-06-23 |
Alza Corporation |
Controlled release formulations exhibiting an ascending rate of release
|
JP2007512350A
(ja)
*
|
2003-11-25 |
2007-05-17 |
エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド |
カルベジロール組成物の治療および送達方法
|
EP1691789B1
(en)
|
2003-11-25 |
2017-12-20 |
SmithKline Beecham (Cork) Limited |
Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
|
US7201920B2
(en)
|
2003-11-26 |
2007-04-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of opioid containing dosage forms
|
US20050281875A1
(en)
*
|
2003-12-17 |
2005-12-22 |
Sovereign Pharmaceuticals, Ltd. |
Promethazine containing dosage form
|
US20050232986A1
(en)
*
|
2003-12-17 |
2005-10-20 |
David Brown |
Dosage form containing promethazine and another drug
|
US7670624B2
(en)
*
|
2004-01-29 |
2010-03-02 |
Astella Pharma Inc. |
Gastrointestinal-specific multiple drug release system
|
SI1566173T1
(sl)
*
|
2004-02-20 |
2006-12-31 |
Mattern Udo |
Farmacevtska zmes za oralno aplikacijo in postopek njene priprave
|
US7713550B2
(en)
*
|
2004-06-15 |
2010-05-11 |
Andrx Corporation |
Controlled release sodium valproate formulation
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
US8541026B2
(en)
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
US20060110327A1
(en)
*
|
2004-11-24 |
2006-05-25 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
US20080152595A1
(en)
*
|
2004-11-24 |
2008-06-26 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
US20060177380A1
(en)
*
|
2004-11-24 |
2006-08-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
EP1845968A2
(en)
|
2004-11-24 |
2007-10-24 |
Neuromolecular Pharmaceuticals, Inc |
Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
|
US20070231268A1
(en)
*
|
2004-11-24 |
2007-10-04 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
KR20070102563A
(ko)
*
|
2005-01-26 |
2007-10-18 |
엘란 파마 인터내셔널 리미티드 |
정신병치료제를 함유하는 조절방출형 조성물
|
EP2243475B1
(en)
|
2005-04-06 |
2016-01-13 |
Adamas Pharmaceuticals, Inc. |
Combination of memantine and donepezil for treatment of CNS disorders
|
US7884136B2
(en)
|
2005-06-27 |
2011-02-08 |
Biovail Laboratories International S.R.L. |
Modified-release formulations of a bupropion salt
|
WO2007031887A2
(en)
*
|
2005-08-30 |
2007-03-22 |
Nicholas Piramal India Limited |
Extended release pharmaceutical composition of metformin and a process for producing it
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US7910126B2
(en)
*
|
2006-03-20 |
2011-03-22 |
Teva Women's Health, Inc. |
Flexible, compressed intravaginal rings, methods of making and using the same, and apparatus for making the same
|
JP5457830B2
(ja)
|
2006-04-03 |
2014-04-02 |
オディディ,イサ |
オルガノゾル被膜を含む制御放出送達デバイス
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
EP2155167A2
(en)
|
2007-06-04 |
2010-02-24 |
Egalet A/S |
Controlled release pharmaceutical compositions for prolonged effect
|
EP2315527A4
(en)
*
|
2008-08-13 |
2013-03-06 |
James Messina |
WIDE SPECTRUM ANIMAL REPELLENT AND METHOD
|
US20110092493A1
(en)
*
|
2008-09-24 |
2011-04-21 |
Clark Levi |
Dose-controlled transdermal promethazine compositions and methods of use
|
US9005660B2
(en)
|
2009-02-06 |
2015-04-14 |
Egalet Ltd. |
Immediate release composition resistant to abuse by intake of alcohol
|
NZ603579A
(en)
|
2009-06-24 |
2014-02-28 |
Egalet Ltd |
Controlled release formulations
|
EP3064064A1
(en)
*
|
2009-09-30 |
2016-09-07 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse
|
CA2994873A1
(en)
|
2009-12-02 |
2011-06-09 |
Adamas Pharmaceuticals, Inc. |
Amantadine compositions and methods of use
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
CN104873455B
(zh)
|
2010-12-22 |
2023-09-12 |
普渡制药公司 |
包覆的抗篡改控制释放剂型
|
CN103327969A
(zh)
|
2010-12-23 |
2013-09-25 |
普渡制药公司 |
抗篡改固体口服剂型
|
US9271486B2
(en)
|
2011-11-10 |
2016-03-01 |
James J. Messina |
Combination animal repellents
|
BR112015000150A2
(pt)
|
2012-07-06 |
2017-06-27 |
Egalet Ltd |
composições farmacêuticas dissuasoras de abuso de liberação controlada
|
WO2014081616A1
(en)
*
|
2012-11-21 |
2014-05-30 |
Merck Sharp & Dohme Corp. |
Preparation of precursors for leukotriene antagonists
|
JP5922851B2
(ja)
|
2012-11-30 |
2016-05-24 |
アキュラ・ファーマシューティカルズ・インコーポレーテッド |
活性医薬成分の自己制御放出
|
WO2014123899A1
(en)
|
2013-02-05 |
2014-08-14 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
WO2014204933A1
(en)
|
2013-06-17 |
2014-12-24 |
Adamas Pharmaceuticals, Inc. |
Amantadine compositions and methods of use
|
AU2015237723B2
(en)
|
2014-03-26 |
2018-04-26 |
Sun Pharma Advanced Research Company Ltd. |
Abuse deterrent immediate release biphasic matrix solid dosage form
|
WO2017040607A1
(en)
|
2015-08-31 |
2017-03-09 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for self-regulated release of active pharmaceutical ingredient
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
WO2018002673A1
(en)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Novel formulations of angiotensin ii receptor antagonists
|
US10213393B1
(en)
|
2018-02-15 |
2019-02-26 |
Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság |
Composition and method for treating neurological disease
|
US10213394B1
(en)
|
2018-02-15 |
2019-02-26 |
Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság |
Composition and method for treating neurological disease
|
US20190247331A1
(en)
|
2018-02-15 |
2019-08-15 |
Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság |
Composition and method for treating neurological disease
|